Scarica l'app Stockscreener
13.98
1.27%
-0.165
Precedente Chiudi:
$14.15
Aprire:
$14.17
Volume 24 ore:
335.13K
Relative Volume:
0.43
Capitalizzazione di mercato:
$909.85M
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-5.1227
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
-2.44%
1M Prestazione:
+1.97%
6M Prestazione:
+35.63%
1 anno Prestazione:
+15.93%
Intervallo 1D:
$13.90
$14.46
Intervallo di 1 settimana:
$13.41
$15.15
Portata 52W:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.96 | 944.39M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.54 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.61 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.89 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
675.86 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.86 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com India
Aldosterone Synthase Inhibitors Market is evolving rapidly - openPR.com
What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive stock market forecasts - jammulinksnews.com
How volatile is Mineralys Therapeutics Inc. stock compared to the marketUnlock your trading potential today - jammulinksnews.com
Intrinsic Value of Mineralys Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAccurate Technical Trend Reversal Picks Detected - metal.it
Will Mineralys Therapeutics Inc. stock split in the near futureTrend Analysis for Safer Trades Gains Popularity - metal.it
Is Mineralys Therapeutics Inc. a growth stock or a value stockExceptional market positioning - jammulinksnews.com
What are Mineralys Therapeutics Inc. company’s key revenue driversAchieve breakthrough financial results - jammulinksnews.com
How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Dynamic capital growth - jammulinksnews.com
Why is Mineralys Therapeutics Inc. stock attracting strong analyst attentionOutstanding trading profits - jammulinksnews.com
What are the latest earnings results for Mineralys Therapeutics Inc.Get real-time updates on market trends - jammulinksnews.com
What are the technical indicators suggesting about Mineralys Therapeutics Inc.Unrivaled growth potential - jammulinksnews.com
Is Mineralys Therapeutics Inc. stock overvalued or undervaluedCapitalize on market shifts with expert advice - jammulinksnews.com
What is Mineralys Therapeutics Inc. company’s growth strategyPowerful market insights - jammulinksnews.com
How strong is Mineralys Therapeutics Inc. company’s balance sheetBuild a portfolio that grows with the market - jammulinksnews.com
What makes Mineralys Therapeutics Inc. stock price move sharplyFree Investment Group - metal.it
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? - Zacks Investment Research
What analysts say about Mineralys Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why - Yahoo Finance
Is Mineralys Therapeutics Inc. stock overhyped or has real potentialHigh-octane financial growth - jammulinksnews.com
Mineralys Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - Autocar Professional
How high can Mineralys Therapeutics Inc. stock price go in 2025Breakthrough capital growth - jammulinksnews.com
Is Mineralys Therapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
What drives Mineralys Therapeutics Inc. stock priceTriple-digit return opportunities - Autocar Professional
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mineralys Therapeutics Inc Azioni (MLYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levy Adam Scott | CFO and Secretary |
Jul 28 '25 |
Sale |
14.04 |
12,946 |
181,803 |
193,666 |
| Levy Adam Scott | CFO and Secretary |
Jul 29 '25 |
Sale |
14.00 |
807 |
11,302 |
192,859 |
0.47%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):